TIGIT Disruption Boosts Low-Avidity T Cell Tumor Attack

Why It Matters

By unlocking the latent potential of low‑avidity T cells, TIGIT disruption could expand effective immunotherapy to tumor types that currently resist treatment, accelerating pipeline diversification for biotech firms.

Key Takeaways

• TIGIT knockout enhances low‑avidity T cell cytotoxicity
• Preclinical models show reduced tumor growth
• Combination with checkpoint inhibitors further improves outcomes
• Strategy targets immunologically “cold” tumors
• Potential for next‑gen immunotherapy pipelines

Pulse Analysis

TIGIT, a co‑inhibitory receptor expressed on exhausted T cells, has emerged as a critical checkpoint in the tumor microenvironment. While high‑affinity T cells have dominated immunotherapy research, the majority of tumor‑infiltrating lymphocytes are low‑avidity, recognizing tumor antigens weakly and often being sidelined by current therapies. Recent genetic studies reveal that removing TIGIT lifts this brake, allowing low‑avidity T cells to proliferate, secrete cytokines, and execute cytotoxic functions that were previously muted. This mechanistic insight reshapes our understanding of T‑cell diversity and its therapeutic relevance.

In vivo experiments using syngeneic mouse tumor models showed that TIGIT‑deficient T cells infiltrated tumors at higher densities and achieved up to a 60% reduction in tumor volume compared with controls. When combined with PD‑1 or CTLA‑4 blockade, the anti‑tumor effect amplified, suggesting synergistic pathways that can be co‑targeted. The enhanced activity stems from restored metabolic fitness and increased expression of activation markers such as CD69 and granzyme B. Importantly, the approach did not trigger overt autoimmunity, indicating a favorable safety profile for translational development.

For the biotech and pharmaceutical sectors, these results open a new pipeline opportunity. Companies can explore CRISPR‑based TIGIT knock‑out in autologous T‑cell products or develop small‑molecule inhibitors that mimic the genetic effect. Clinical trials focusing on solid tumors with low mutational burden—historically resistant to checkpoint blockade—could benefit from this strategy. As investors seek differentiated immunotherapies, TIGIT disruption positions itself as a compelling candidate to broaden the market share of next‑generation cancer treatments.